Assignee
SHIRE HUMAN GENETIC THERAPIES
US77 patents
Top patents by PatentIndex Score
US9522176B2Dec 20, 2016
MRNA therapy for phenylketonuria
SHIRE HUMAN GENETIC THERAPIES38 citations98
US9308281B2Apr 12, 2016
MRNA therapy for Fabry disease
SHIRE HUMAN GENETIC THERAPIES40 citations98
US9061021B2Jun 23, 2015
mRNA for use in treatment of human genetic diseases
SHIRE HUMAN GENETIC THERAPIES43 citations98
US9629804B2Apr 25, 2017
Lipid formulations for delivery of messenger RNA
SHIRE HUMAN GENETIC THERAPIES60 citations97
US9181321B2Nov 10, 2015
CFTR mRNA compositions and related methods and uses
SHIRE HUMAN GENETIC THERAPIES50 citations97
US9597413B2Mar 21, 2017
Pulmonary delivery of mRNA
SHIRE HUMAN GENETIC THERAPIES17 citations96
US9713626B2Jul 25, 2017
CFTR mRNA compositions and related methods and uses
SHIRE HUMAN GENETIC THERAPIES23 citations94
US9546128B2Jan 17, 2017
Ionizable cationic lipids
SHIRE HUMAN GENETIC THERAPIES12 citations93
US7833766B2Nov 16, 2010
Stabilized compositions of proteins having a free thiol moiety
SHIRE HUMAN GENETIC THERAPIES13 citations92
US7833742B2Nov 16, 2010
Treatment of α-galactosidase A deficiency
SHIRE HUMAN GENETIC THERAPIES21 citations91
US11033459B2Jun 15, 2021
Modular vial adapter
SHIRE HUMAN GENETIC THERAPIES22 citations90
US9814764B2Nov 14, 2017
Treatment of sanfilippo syndrome type b by intrathecal administration of alpha-n-acetylglucosaminidase
SHIRE HUMAN GENETIC THERAPIES9 citations90
US9220677B2Dec 29, 2015
Methods and compositions for CNS delivery of iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES16 citations90
US9051556B2Jun 9, 2015
Purification of iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES13 citations90
US7138262B1Nov 21, 2006
High mannose proteins and methods of making high mannose proteins
SHIRE HUMAN GENETIC THERAPIES32 citations85
US10245229B2Apr 2, 2019
Pulmonary delivery of mRNA to non-lung target cells
SHIRE HUMAN GENETIC THERAPIES8 citations84
US11260112B2Mar 1, 2022
Methods and compositions for CNS delivery of iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES2 citations83
US10556015B2Feb 11, 2020
Lysosomal targeting of enzymes, and uses thereof
SHIRE HUMAN GENETIC THERAPIES7 citations83
US10456454B2Oct 29, 2019
CNS delivery of therapeutic agents
SHIRE HUMAN GENETIC THERAPIES6 citations83
US11065308B2Jul 20, 2021
Methods and compositions for CNS delivery of heparan n-sulfatase
SHIRE HUMAN GENETIC THERAPIES6 citations82
US9492511B2Nov 15, 2016
Methods and compositions for treatment of hunter syndrome
SHIRE HUMAN GENETIC THERAPIES4 citations82
US9206235B2Dec 8, 2015
Peptide linkers for polypeptide compositions and methods for using same
SHIRE HUMAN GENETIC THERAPIES8 citations82
US9150841B2Oct 6, 2015
Cells for producing recombinant iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES8 citations82
US11065307B2Jul 20, 2021
Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety
SHIRE HUMAN GENETIC THERAPIES2 citations81
US10730874B2Aug 4, 2020
Inhibitors of plasma kallikrein and uses thereof
SHIRE HUMAN GENETIC THERAPIES7 citations80
US9682129B2Jun 20, 2017
Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES5 citations78
US11471516B2Oct 18, 2022
CNS delivery of therapeutic agents
SHIRE HUMAN GENETIC THERAPIES1 citations72
US11530393B2Dec 20, 2022
Compositions comprising iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES2 citations71
US11229661B2Jan 25, 2022
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SHIRE HUMAN GENETIC THERAPIES2 citations71
US10344270B2Jul 9, 2019
Methods and compositions for treatment of Hunter syndrome
SHIRE HUMAN GENETIC THERAPIES2 citations71
US9932568B2Apr 3, 2018
Peptide linkers for polypeptide compositions and methods for using same
SHIRE HUMAN GENETIC THERAPIES2 citations71
US9932377B2Apr 3, 2018
Mitochondrial targeting and therapeutic use thereof
SHIRE HUMAN GENETIC THERAPIES2 citations71
US9523113B2Dec 20, 2016
Treatment of α-galactosidase A deficiency
SHIRE HUMAN GENETIC THERAPIES3 citations71
US10603364B2Mar 31, 2020
Lysosomal targeting and uses thereof
SHIRE HUMAN GENETIC THERAPIES2 citations70
US10722559B2Jul 28, 2020
Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
SHIRE HUMAN GENETIC THERAPIES5 citations68
US10660944B2May 26, 2020
Stable formulations for CNS delivery of arylsulfatase A
SHIRE HUMAN GENETIC THERAPIES5 citations68
US9957324B2May 1, 2018
Anti-FLT-1 antibodies in treating duchenne muscular dystrophy
SHIRE HUMAN GENETIC THERAPIES5 citations68
US9603908B2Mar 28, 2017
Subcutaneous administration of iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES2 citations68
US10568941B2Feb 25, 2020
Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES1 citations67
US7410799B2Aug 12, 2008
In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
SHIRE HUMAN GENETIC THERAPIES1 citations63
US12350267B2Jul 8, 2025
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SHIRE HUMAN GENETIC THERAPIES0 citations61
US12145959B2Nov 19, 2024
Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
SHIRE HUMAN GENETIC THERAPIES0 citations61
US11376251B2Jul 5, 2022
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SHIRE HUMAN GENETIC THERAPIES0 citations61
US10711065B2Jul 14, 2020
Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
SHIRE HUMAN GENETIC THERAPIES1 citations61
US10646554B2May 12, 2020
Methods and compositions for CNS delivery of arylsulfatase A
SHIRE HUMAN GENETIC THERAPIES0 citations60
US11013864B2May 25, 2021
Small unit dosage plunger rod stops
SHIRE HUMAN GENETIC THERAPIES0 citations58
US12435146B2Oct 7, 2025
Anti-Flt-1 antibodies for treating Duchenne muscular dystrophy
SHIRE HUMAN GENETIC THERAPIES0 citations57
US10896749B2Jan 19, 2021
Drug monitoring tool
SHIRE HUMAN GENETIC THERAPIES1 citations56
US10695395B2Jun 30, 2020
Collagen 7 compositions and methods of using the same
SHIRE HUMAN GENETIC THERAPIES1 citations56
US11059906B2Jul 13, 2021
Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
SHIRE HUMAN GENETIC THERAPIES0 citations55
Showing the top 50 of 77 patents by PatentIndex Score.